|
|
Profile
|
Delegates :
Noriyuki Onishi |
|
Incorporated :
February 22 , 2024 |
Paid in Capital :
Million yen |
Employees :
2 人 |
Address :
Chiba University Inohana Innovation Plaza 1-8-15 Inohana, Chuo-ku, Chiba-shi CHIBA
〒260-0856
|
TEL/FAX :
+81-80-7469-5941 / +81-43-291-1213 |
URL：
https://segnos.co.jp/ |
Attachment :
 SEGNOS会社案内_(1).pdf [ 1.4MiB ] |
Mission/Background :
SEGNOS Co., Ltd. is a biotechnology startup developing innovative separation and diagnostic technologies based on proprietary stimuli-responsive magnetic nanoparticles. Founded through the fusion of corporate carve-out innovations and university-originated technologies, the company aims to become a global niche leader in magnetic nanoparticle-based diagnostics and bioseparation. SEGNOS is developing ultra-fast and ultra-sensitive diagnostic platforms for infectious diseases, neurodegenerative disorders, and preventive healthcare. Its mission is to contribute to healthcare digital transformation, early disease detection, and the extension of healthy life expectancy through next-generation diagnostic technologies. |
|
Technology & Business
|
SEGNOS has developed Therma-Max, a thermo-responsive magnetic nanoparticle, and Vira-Max, a PEG-responsive magnetic nanoparticle. These technologies enable both rapid magnetic separation and significantly enhanced detection sensitivity compared with conventional magnetic beads. The company is also developing AptIa, a highly sensitive diagnostic platform utilizing DNA aptamers, and ThermaLISA, a next-generation assay technology capable of performing diagnostic testing from a single drop of blood. Applications include infectious disease detection, Alzheimer's disease risk assessment, clinical diagnostics, high-throughput screening, and life science research.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Therma-Max
|
Launched
|
Thermo-responsive magnetic nanoparticles for rapid and highly sensitive bioseparation
|
Expand sales and collaborative projects
|
Vira-Max
|
Launched
|
PEG-responsive magnetic nanoparticles for sample concentration and diagnostics
|
Market expansion and application development
|
AptIa Technology
|
Discovery
|
DNA aptamer-based ultra-sensitive diagnostic platform
|
Commercialization and partner acquisition
|
ThermaLISA
|
Discovery
|
Single-drop blood diagnostic technology for early disease detection
|
Alzheimer's disease testing development
|
SegnoSCAN
|
Discovery
|
High-throughput screening technology platform
|
Strategic partnerships and commercialization
|
|
Highlights
|
Therma-Max and Vira-Max were certified as Chiba Monozukuri Certified Products. SEGNOS received the Grand Prize at the 23rd Venture Cup CHIBA and the Startup Award at the 30th Chiba Genki-Innovation Awards. The company developed an ultra-high-sensitivity molecular counting technology in collaboration with the Tokyo Metropolitan Institute for Geriatrics and Gerontology and recently filed patent applications for its new high-throughput screening platform, SegnoSCAN.
|
|
Hot news
|
SEGNOS recently developed an ultra-high-sensitivity molecular counting technology and its proprietary SegnoSCAN high-throughput screening platform, for which patent applications have been filed. The company is also advancing a blood-based Alzheimer's disease risk assessment technology that requires only a single drop of blood, supporting the future of decentralized and preventive healthcare.
|
|
Alliance strategy
|
SEGNOS seeks strategic partnerships with pharmaceutical companies, diagnostic manufacturers, medical device companies, universities, and research institutes. The company is interested in collaborative research, technology licensing, business alliances, and global market expansion opportunities related to magnetic nanoparticle technologies, high-sensitivity diagnostics, neurodegenerative disease testing, and life science applications.
|
|
|